miR-877-3p as a Potential Tumour Suppressor of Oesophageal Squamous Cell Carcinoma

Fukuda, Takuma; Baba, Hayato; Okumura, Tomoyuki; Kanda, Mitsuro; Akashi, Takuya; Tanaka, Haruyoshi; Miwa, Takeshi; Watanabe, Tôru; Hirano, Katsuhisa; Sekine, Satoshi; Hashimoto, Isaya; Shibuya, Kazuto; Hojo, Satoru; Yoshioka, Isaku; Matsui, Koshi; Kodera, Yasuhiro; Fujii, Tsutomu

doi:10.21873/anticanres.16131

Cited by 4 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Peptide or protein-based drugs exhibit high specificity and efficiency in the clinical treatment of ESCC, which suggests that proteins encoded by circRNAs may serve as potential sources for screening therapeutic drugs for ESCC (175)(176)(177). Indeed, studies have examined the potential of ncRNAs as target in the treatment of ESCC, such as miR-877-3p, miRNA-20b-5p and circFoxo3 (178)(179)(180). However, the therapeutic efficacy of these ncRNA for ESCC in the clinic still requires in-depth study.…”

Section: Discussionmentioning

confidence: 99%

Non‑coding RNA: A promising diagnostic biomarker and therapeutic target for esophageal squamous cell carcinoma (Review)

Zhang,

Wang,

Gao

et al. 2024

Oncol Lett

View full text Add to dashboard Cite

Esophageal cancer (EC) is a common form of malignant tumor in the digestive system that is classified into two types: Esophageal squamous cell carcinomas (ESCC) and esophageal adenocarcinoma. ESCC is known for its early onset of symptoms, which can be difficult to identify, as well as its rapid progression and tendency to develop drug resistance to chemotherapy and radiotherapy. These factors contribute to the high incidence of disease and low cure rate. Therefore, a diagnostic biomarker and therapeutic target need to be identified for ESCC. Non-coding RNAs (ncRNAs) are a class of molecules that are transcribed from DNA but do not encode proteins. Initially, ncRNAs were considered to be non-functional segments generated during transcription. However, with advancements in high-throughput sequencing technologies in recent years, ncRNAs have been associated with poor prognosis, drug resistance and progression of ESCC. The present study provides a comprehensive overview of the biogenesis, characteristics and functions of ncRNAs, particularly focusing on microRNA, long ncRNAs and circular RNAs. Furthermore, the ncRNAs that could potentially be used as diagnostic biomarkers and therapeutic targets for ESCC are summarized to highlight their application value and prospects in ESCC.

show abstract

Section: Discussionmentioning

confidence: 99%

Non‑coding RNA: A promising diagnostic biomarker and therapeutic target for esophageal squamous cell carcinoma (Review)

Zhang,

Wang,

Gao

et al. 2024

Oncol Lett

View full text Add to dashboard Cite

show abstract

“…The significant transcriptomes associated with ESCC have been widely investigated through high-throughput approaches. For example, known ESCC-related miRNAs include miR-23b-5p, miR-877-3p, and miR-17-92, among others (13)(14)(15)(16). Several published works demonstrated that chemotherapy resistance can be affected by mRNAs like TUG1, ZFX, and NRF2, and miRNAs like miR-130a-3p, miR-125a-5p, and miR-224 (17)(18)(19)(20)(21).…”

Section: Discussionmentioning

confidence: 99%

Use of exosome transcriptome-based analysis to identify novel biomarkers in patients with locally advanced esophageal squamous cell carcinoma undergoing neoadjuvant chemoradiotherapy

Yang¹,

Zhang²,

Liu³

et al. 2023

Ann Transl Med

View full text Add to dashboard Cite

Background: The prognosis of esophageal squamous cell carcinoma (ESCC) is improved by neoadjuvant chemoradiotherapy (nCRT), especially for patients with pathologic complete response (pCR). Despite the efforts to predict treatment response using multimodality, no molecule has proven to be a strong biomarker.This study aimed to profile the expression of exosome transcriptome that could predict pCR in ESCC before and after nCRT.Methods: We collected paired blood samples of 15 patients with ESCC who received nCRT and radical surgery. They were divided into 3 groups: (A) residual tumor in the first clinical response evaluation (CRE-1), (B) no residual tumor in CRE-1 but with residual tumor in CRE-2 which was performed after 5-6 weeks, and (C) no residual tumor in CRE-1 or CRE-2. For each patient, the blood sample was collected before nCRT (time point 0); and then 6 weeks after nCRT, the clinical response was evaluated, and another blood sample was collected (time point 1).Results: Using the intersection of different sets, we found 23 progression-associated messenger RNAs (mRNAs) and 67 remission-associated mRNAs. Between remission-associated mRNAs and the targets of progression-associated (carcinogenic) microRNAs (miRNAs), the intersection was acquired, and 2 miRNA-mRNA networks (IFIT2-miR-3615-IFIT2-miR-484 and BTN3A3-miR-6803-3p) were identified. Among the intersection of progression-associated (carcinogenic) mRNAs and the targets of remission-associated miRNAs, there is a network with miR-132-3p (remission-associated miRNA) located at the core, matched with DICER1, KLHL8, ANKRD12, ASH1L, and IMP4.Conclusions: Our findings identified altered plasma exosome RNAs among the different groups and between different time points of nCRT, as well as the corresponding enrichments and regulatory networks, which may serve as potentially predictors of treatment response for patients with ESCC after nCRT.

show abstract

“…Esophageal cancer is one of the worst cancers regarding prognosis and numerous studies have been conducted in order to find independent prognostic factors and anti-tumor molecules (12,13). We then focused on T RM .…”

Section: Discussionmentioning

confidence: 99%

Usefulness of Biopsy Specimens for Evaluating CD103⁺Tumor-resident Memory T Cells in Esophageal Cancer

NATSUKI,

MIKI,

TANAKA

et al. 2023

Anticancer Res

View full text Add to dashboard Cite

show abstract

miR-877-3p as a Potential Tumour Suppressor of Oesophageal Squamous Cell Carcinoma

Cited by 4 publications

References 0 publications

Non‑coding RNA: A promising diagnostic biomarker and therapeutic target for esophageal squamous cell carcinoma (Review)

Non‑coding RNA: A promising diagnostic biomarker and therapeutic target for esophageal squamous cell carcinoma (Review)

Use of exosome transcriptome-based analysis to identify novel biomarkers in patients with locally advanced esophageal squamous cell carcinoma undergoing neoadjuvant chemoradiotherapy

Usefulness of Biopsy Specimens for Evaluating CD103⁺Tumor-resident Memory T Cells in Esophageal Cancer

Contact Info

Product

Resources

About

miR-877-3p as a Potential Tumour Suppressor of Oesophageal Squamous Cell Carcinoma

Cited by 4 publications

References 0 publications

Non‑coding RNA: A promising diagnostic biomarker and therapeutic target for esophageal squamous cell carcinoma (Review)

Non‑coding RNA: A promising diagnostic biomarker and therapeutic target for esophageal squamous cell carcinoma (Review)

Use of exosome transcriptome-based analysis to identify novel biomarkers in patients with locally advanced esophageal squamous cell carcinoma undergoing neoadjuvant chemoradiotherapy

Usefulness of Biopsy Specimens for Evaluating CD103+Tumor-resident Memory T Cells in Esophageal Cancer

Contact Info

Product

Resources

About

Usefulness of Biopsy Specimens for Evaluating CD103⁺Tumor-resident Memory T Cells in Esophageal Cancer